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We present ﬁve cases of cytomegalovirus (CMV) pneumonitis occurring in patients after recent T cell
deplete allogeneic stem cell transplantation (AlloHSCT). These cases were complicated by an organising
pneumonia (during the recovery period) with a predominantly central peribronchial pattern. All patients
presented with evidence of active CMV pneumonitis which was treated successfully with anti-viral
therapy but was followed by persistent severe dyspnoea, cough and hypoxia. High resolution
computed tomography (HRCT) imaging showed widespread central peribronchial consolidation with
traction bronchiectasis. There was a marked clinical and physiological improvement after treatment with
systemic corticosteroids. However, in all patients the lung function remained abnormal and in some
cases imaging revealed a ﬁbrosing lung disease. These cases represent a previously undescribed central
peribronchial pattern of organising pneumonia complicating CMV pneumonitis that can result in chronic
lung damage.
© 2017 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
T cell deplete allogeneic stem cell transplantation (AlloHSCT) is
frequently complicated by non-infective and infective lung com-
plications. Infective lung complications include cytomegalovirus
(CMV) pneumonitis, which usually presents with cough, dyspnoea
and increasing hypoxia associated with systemic reactivation of
CMV infection. The radiological pattern on high resolution
computed tomography (HRCT) is variable but most commonly
shows widespread bilateral ground glass inﬁltrates [1,2]. Organis-
ing pneumonia is an uncommon non-infective respiratory
complication of T cell deplete AlloHSCT. It can be idiopathic or it can
occur as a complication of infection, radiotherapy or drug therapy
[3,4,5]. In organising pneumonia, HRCT usually demonstrates pat-
chy subpleural consolidation with no particular lobar or zonal
predominance [6]. Treatment with systemic corticosteroids is
usually highly effective [7,8]. Here we describe ﬁve cases of CMV
pneumonitis affecting AlloHSCT recipients (patient characteristics
shown in Table 1) complicated by a probable organising pneumonia
with a distinctive clinical and radiological course.. Cuadrado).
n open access article under the CC1.1. Case series
1.1.1. Patient 1
A 28 year old female non-smoker received a T deplete matched
unrelated donor AlloHSCT for refractory Hodgkin's lymphoma. On
day þ25 post-AlloHSCT, serum polymerase chain reaction (PCR)
indicated systemic reactivation of CMV with a blood viral load that
reached a maximum of 55000 copies/ml by day þ39 and a CRP of
50 mg/L (normal range 0e5). This was associated with progressive
dyspnoea and an oxygen saturation of 86% on air. HRCT on dayþ39
showed a bilateral symmetrical ground glass inﬁltrate with inter-
lobular septal thickening compatible with a viral pneumonitis
[Fig.1A(i)]. CMV PCR viral load in bronchoalveolar lavage (BAL) ﬂuid
obtained on day þ43 was 3400 copies/ml; microbiological and
cytology tests for other pathogens were negative. After treatment
with intravenous foscarnet the patient became apyrexial and the
blood CMV viral load negative, with no clinical evidence of active
infection. However, the patient remained dyspnoeic [Medical
Research Council (MRC) dyspnoea scale grade 4] with an oxygen
saturation of 88% on air. HRCT on day þ57 showed dense central
peribronchial consolidation with traction bronchiectasis and a
perilobular pattern of consolidation in the periphery associated
with pleuro-parenchymal distortion [Fig. 1A(ii)]. The patient wasBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Case demography and clinical characteristics CT scan was obtained.
Patient Case 1 Case 2 Case 3 Case 4 Case 5
Age 28 60 15 19 65
Sex Female Female Female Female Female
Underlying disease Hodgkin's Lymphoma Follicular
Lymphoma
Acute Lymphoblastic
Leukaemia
Fanconi Anaemia Acute Myeloid Leukaemia
Transplant
conditioning
Carmustine
Cytarabine
Etoposide
Alemtuzumab
Melphalan
Alemtuzumab
Fludarabine
Melphalan
Cyclophosphamide
Alemtuzumab
TBI
Fludarabine
Melphalan
Alemtuzumab
Fludarabine
Melphalan
Alemtuzumab
CMV serostatus
patient/donor
Positive/Positive Positive/Positive Negative/Negative Positive/Negative Positive/Negative
Date of CMV
reactivation
Day þ25 Day þ22 Day þ23 Day þ26 Day þ74
Maximum viral
title (copies/ml)
55000 26000 69000 15000 1200000
Diagnostic criteria
for pneumonia
Bilateral symmetrical
ground glass inﬁltrates
with interlobular septal
thickening
Diffuse bilateral ground
glass opaciﬁcation with
nodular septal
thickening
Widespread bronchocentric
consolidation with ground glass
opaciﬁcation and peripheral sparing
Diffuse bilateral ground
inﬁltrates with
interlobular septal
thickening
Diffuse bilateral ground glass
inﬁltrate with peripheral
sparing and basal septal
thickening
Date of HRCT
showing
organising
pneumonia
Day þ57 Day þ136 Day þ73 Dayþ108 Day þ110
CMV titres changes
(copies/ml)
457 Not detected Not detected Not detected 1000
Treatment for
organising
pneumonia,
steroids dose
reduction
500 mg
methylprednisolone  3
days and reducing
dose  9 months
40 mg/day
prednisolone reducing
dose  6 months
500mg of intravenous
methylprednisolone  3 days, followed
by a reducing course of oral
prednisolone  3 months. Patient died
40 mg/day
prednisolone
remaining on low dose
(2mg) longterm (2
years)
500mg
methylprednisolone  3 days
and a reducing course of oral
prednisolone  12 months
M.M. Cuadrado et al. / Respiratory Medicine Case Reports 20 (2017) 184e187 185treated with 500 mg of intravenous methylprednisolone for three
days followed by a prolonged reducing course of oral prednisolone
over nine months, starting at 30 mg/day. Her dyspnoea improved
and oxygen saturations increased to 96% on air. Allowing for
breathing artefact, a Positron Emission Tomography (PET) CT on
day þ211 showed marked improvement in the bronchocentric and
peripheral consolidation [Fig. 1A(iii)]. The patient's exercise toler-
ance returned to normal although pulmonary function tests (PFTs)
on day þ275 showed a persistent reduction in her transfer factor
(Table 2).1.1.2. Patient 2
A 60 year old female non-smoker received a T deplete matched
unrelated donor AlloHSCT for relapsed stage 4 follicular lymphoma,
complicated by severe mucositis and acute skin graft versus host
disease (GvHD). On day þ22, PCR indicated systemic reactivation of
CMV with a blood viral load of 22000 copies/ml. The patient
developed cough and dyspnoea with an oxygen saturation of 88%
on air. HCRT on day þ26 showed diffuse bilateral ground glass
opaciﬁcation with nodular septal thickening compatible with viral
infection [Fig. 1B(i)]. Treatment with ganciclovir resulted in rapid
clinical improvement and the serum CMV PCR became negative.Table 2
Recovery lung function testing data (none available for case 3 as the patient died).
Case 1 Case 2 Case 4 Case 5
Day tested þ275 þ720 þ730 þ190
FEV1 (%predicted) 2.85 (95%) 2.25 (96%) 0.97 (33%) 2.01 (105%)
FVC (%predicted) 3.27 (95%) 2.64 (95%) 1.68 (50%) 2.42 (102%)
TLC (%predicted) 4.91 (103%) 4.53 (89%) 3.27 (74%) 4.64 (102%)
TLCO (% predicted) 4.70 (53%) 3.46 (45%) 3.67 (42%) 4.09 (58%)
KCO (% predicted) 1.29 (69%) 0.90 (60%) 1.75 (89%) 1.51 (75%)However, CMV reactivation recurred on day þ118 and treatment
had to be restarted. On day þ130, the patient deteriorated with
cough, dyspnoea (MRC grade 4), and an oxygen saturation of 89% on
air. CMV blood viral load reached 26000 copies/ml on day þ134
which represented the peak viral load. HRCT on day þ136
demonstrated bilateral central and subpleural consolidation (with
some traction bronchiectasis) and perilobular changes in the pe-
riphery consistent with an organising pneumonia [Fig. 1B(ii)]. The
patient was commenced on a six month reducing course of pred-
nisolone starting at 40 mg/day. Within three weeks her oxygen
saturation returned to normal at rest, but she remained dyspnoeic
on exertion (MRC grade 2) with a persistent defect in her transfer
factor (Table 2). HRCT at dayþ322 showed residual band-like areas
of consolidation, increased architectural distortion, traction bron-
chiectasis and volume loss consistent with a ﬁbrosing organising
pneumonia [Fig. 1B(iii)].
1.1.3. Patient 3
A 15 year old female non-smoker received a T deplete matched
unrelated donor AlloHSCT for acute lymphoblastic leukaemia.
Although both patient and donor were CMV negative, on day þ23
she developed pyrexia and PCR demonstrated CMV viraemia
reaching a maximum of 69000 copies/ml by day þ35. This was
associated with progressive dyspnoea and hypoxia and an oxygen
saturation of 88% on air. HCRT on day þ42 showed widespread
peribronchial consolidation with ground glass opaciﬁcation and
peripheral sparing [Fig. 1C(i)] compatible with a CMV pneumonitis.
Treatment with intravenous foscarnet and pooled immunoglobu-
lins caused a rapid improvement in her condition and blood CMV
PCR became negative by day þ60. On day þ73, the dyspnoea (MRC
grade 3) and hypoxaemia recurred. Repeat HRCT demonstrated
dense consolidation forming perilobular bands, associated with
pleuro-parenchymal distortion and traction bronchiectasis,
consistent with a ﬁbrosing organising pneumonia [Fig. 1C(ii) &
Fig. 1. HRCT appearances for cases 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E). The number above each panel refers to how many days after ASCT the HRCT scan was performed.
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bronchial biopsy showed alveolar damage (likely infectious in
origin) with mild interstitial ﬁbrosis, focal ﬁbroblastic reaction and
congestion but no visible microorganisms or inclusion bodies. She
was treated with 500mg of intravenous methylprednisolone for
three days, followed by a reducing course of oral prednisolone
starting at 30 mg/day. The dyspnoea improved with oxygen satu-
rations increasing to 96% on air by day þ95. The patient died on
day þ180 due to pulmonary haemorrhage complicating a probable
bacterial pneumonia. A post-mortem was not performed.
1.1.4. Patient 4
A 19 year old female non-smoker was treated with a T deplete
sibling AlloHSCT for Fanconi Anaemia. On day þ26 PCR demon-
strated systemic reactivation of CMV with a maximum viral load of
15000 copies/ml by day þ39. On day þ41 she became dyspnoeic
with an oxygen saturation of 90% on air. HCRT on day þ42 showed
diffuse bilateral ground glass opaciﬁcation (slightly more dense on
the left) with interlobular septal thickening compatible with a CMV
pneumonitis [Fig. 1D(i)]. After treatment with intravenous foscar-
net the patient clinically improved and CMV viral load became
negative by day þ59. On day þ90 she developed cough and dysp-
noea (MRC grade 4). Repeat HRCTon dayþ108 demonstrated dense
bilateral peribronchial consolidation with perilobular changes in
the periphery, traction bronchiectasis and architectural distortion
consistent with a ﬁbrosing organising pneumonia [Fig. 1D(ii)]. BAL
on day þ110 was negative for microorganisms including CMV, and
transbronchial biopsy was not diagnostic showing minimal chronic
inﬂammationwith no CMV inclusions. The patient was treatedwith
a reducing course of prednisolone starting at 40mg daily remaining
on low dose (2mg) long-term. Although her dyspnoea initially
improved, she developed persistent exertional dyspnoea (MRCgrade 3) associated with a severe mixed obstructive/restrictive lung
function defect (Table 2). HRCT on day þ202 showed further scar-
ring with linear bands, progressive volume loss and architectural
distortion [Fig. 1D(iii)].
1.1.5. Patient 5
A 65 year old female non-smoker received a T deplete matched
unrelated donor AlloHSCT for acute myeloid leukaemia. On dayþ74
she developed CMV reactivation with a maximum viral load of
1200000 copies/ml by day þ88 and a CRP of 10.8 mg/L. This was
associated with progressive dyspnoea and an oxygen saturation of
94% on air. HCRTon dayþ83 showed a diffuse bilateral ground glass
inﬁltrate with thickening of the interlobular septa compatible with
a CMV pneumonitis. [Fig. 1E(i)]. Treatment with intravenous fos-
carnet and ganciclovir reduced the CMV viral load to 740 copies/ml
by day þ100 and led to a slow clinical improvement. On day þ104
her dyspnoea deteriorated (MRC grade 4), and repeat HRCT on
day þ110 demonstrated dense peribronchial consolidation with
traction bronchiectasis and architectural distortion [Fig. 1E(ii)].
Treatment with three daily doses of 500mg intravenous methyl-
prednisolone and a reducing course of oral prednisolone starting at
30 mg/day resulted in a normal oxygen saturation on air by
day þ124 and a normal exercise tolerance. Her transfer factor
remained mildly reduced (Table 2).
2. Conclusion
We describe ﬁve similar cases of a biphasic illness compli-
cating the early period after a T cell deplete AlloHSCT. The initial
phase consisted of CMV pneumonitis characterised by clinical
evidence of pneumonia, systemic CMV infection, HRCT ﬁndings
compatible with a viral pneumonitis, and clinical improvement
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ond phase (57e136 days later) with clinical and radiological
features consistent with a distinct form of organising pneumonia.
The second phase was characterised by recurrence of severe
dyspnoea and hypoxia, with a very different and distinct HRCT
pattern comprised of central peribronchial consolidation, trac-
tion bronchiectasis and architectural distortion. When available,
BAL showed no evidence of active infection. The clinical and
radiological features during this phase resembled an atypical
pattern of probable organising pneumonia. Diagnostic conﬁr-
mation would have required a surgical lung biopsy, however this
would have exposed the patients to excessive clinical risk. As
expected with organising pneumonia, there was a signiﬁcant
clinical improvement following treatment with systemic corti-
costeroids. However, all surviving patients had evidence of at
least some long term clinical, radiological and/or lung function
abnormalities indicating chronic lung damage, with the expected
restrictive pattern in three patients. The fourth patient had a
mixed restrictive/obstructive lung function defect, a less common
pattern for organising pneumonia. Unfortunately pre-transplant
and pre-treatment for organising pneumonia lung function
testing was not performed and therefore not available for com-
parison. The central peribronchial pattern of organising pneu-
monia described is an uncommon radiological pattern and the
timing in these ﬁve cases would suggest a unique response to
CMV pneumonitis. However, this is impossible to conﬁrm and
similar reactions could occur to other viral lung infections.
Whether this complication is limited to allograft recipients re-
mains unknown. It is also striking that all ﬁve cases were female,
but the signiﬁcance of this sex bias is unclear. Recognition that
CMV pneumonitis can be complicated by a predominantly centralbronchocentric pattern of organising pneumonia will allow early
identiﬁcation of future cases.Funding
JSB is supported by UCLH Biomedical Research Centre's which
receives funding from the Department of Health's NIHR Biomedical
Research Centre's scheme.References
[1] Jeung Hee Moon, Eun A. Kim, Cytomegalovirus pneumonia: high-resolution CT
ﬁndings in ten non-AIDS immu nocompromised patients, Korean J. Radiol. 1 (2)
(2000 Apr-Jun) 73e78.
[2] Tomas Franquet, S. Kyung, Thin-section CT ﬁndings in 32 immunocompromised
patients with cytomegalovirus pneumonia who do not have AIDS, Am. J.
Roentgenol. 181 (2003) 1059e1063.
[3] Fotios Drakopanagiotakis, Koralia Paschalaki, Muhanned Abu-Hijleh, FCCP.
Cryptogenic and secondary organizing pneumonia: clinical presentation,
radiographic ﬁndings, treatment response, and prognosis, Chest 139 (4) (2011)
893e900.
[4] Nakasone H, M. Onizuka, N. Suzuki, Pre-transplant risk factors for cryptogenic
organizing pneumonia/bronchiolitis obliterans organizing pneumonia after
hematopoietic cell transplantation, Bone Marrow Transpl. 48 (10) (2013 Oct)
1317e1323.
[5] Yanal Alnimer, Samer Salah, Bashar Abuqayas, Kamal Alrabi, Azacitidine-
induced cryptogenic organizing pneumonia: a case report and review of the
literature, J. Med. Case Rep. 10 (2016) 15.
[6] Ju Won Lee, Kyung Soo Lee, Ho Yun Lee, Cryptogenic organizing pneumonia:
serial high-resolution CT ﬁndings in 22 patients, Am. J. Roentgenol. 195 (2010)
916e922.
[7] Suparno Chakrabarti, Collingham, et al., Respiratory virus infections in adult T
Cell e depleted transplant recipients: the roll of cellular immunity, Trans-
plantation 72 (2001) 1460e1463.
[8] J.F. Cordier, Criptogenetic organising pneumonia, Eur. Respir. J. 28 (2) (2006
Aug) 422e446.
